Withings debuted its Body Scan in 2023 as a high-end weighing device incorporating advanced features typically seen in upscale fitness centers or basic medical facilities. The initial version included a six-lead electrocardiogram, detailed body composition analysis by segments, and assessments of nerve function, along with various other capabilities. At CES 2026 in Las Vegas, the firm revealed an upgraded version that incorporates evaluations for high blood pressure and cell vitality, aiming to deliver additional information to help combat long-term diseases linked to contemporary sedentary habits.
The original Body Scan analyzed 40 health markers, but this successor expands to 60, requiring a list format even in promotional descriptions to cover the additions. A standout addition is Impedance Cardiography (ICG), which evaluates the heart's ability to circulate blood effectively to vital organs. Another key feature is Bioimpedance Spectroscopy (BIS), employing a mild electrical signal to measure overall body water content, enabling tracking of cellular aging, viable tissue volume, and metabolic performance.
This information will be analyzed via Withings' clinically approved artificial intelligence system to provide deeper understandings, including probabilities for developing hypertension and blood sugar control. Users will receive assessments of their overall wellness direction based on key metrics, plus recommendations to extend their period of optimal health. Essentially, the brand seeks to establish this device as a comprehensive medical tool at home, guiding individuals toward better lifestyle decisions proactively.
A notable change in design from the prior model involves integrating the device's screen into the extendable handle used for ECG readings, which should simplify viewing results, particularly in low-visibility situations like post-shower weigh-ins without clothing. However, this setup raises potential reliability issues due to the slender connection wire linking the handle to the base unit.
The company anticipates FDA approval to align with a release scheduled for the second quarter of 2026. Pricing for this top-tier product will be substantial, listed at $599.95 in the US, €499.95 in Europe, or £449.95 in the UK, varying by region.